# Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease

> **NCT00925587** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 358 (actual)

## Conditions studied

- Anemia
- Chronic Kidney Disease

## Interventions

- **DRUG:** darbepoetin alfa

## Key facts

- **NCT ID:** NCT00925587
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2012-04
- **Final completion:** 2012-05
- **Target enrollment:** 358 (ACTUAL)
- **Last updated:** 2014-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00925587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00925587, "Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00925587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*